Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newly Discovered Polymorphism May Have Immediate Impact in HCV

This article was originally published in Start Up

Executive Summary

It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.

You may also be interested in...



A New Genetic Connection In Liver Cancer -- As Powerful As Her2/neu In Breast?

New data point to a targeted strategy for treating a significant subset of liver cancers and importantly, provide a biomarker for identifying patients who could benefit from the therapy. It's based on the discovery of a correlation between amplification of a growth factor gene and overexpression of the gene's protein product -- a phenomenon that mirrors the way in which amplified Her2/neu gene expression promotes a subset of breast cancer, which led to the development of Herceptin.

Novartis Follows Its Own Business Development Model into Molecular Diagnostics

Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.

Novartis Follows Its Own Business Development Model into Molecular Diagnostics

Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC091848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel